Cell and gene therapy · CDMO · Built to order
Cell and gene therapy manufacturing, CDMO and vein-to-vein logistics assessment
Which manufacturing model and CDMO fit a cell or gene therapy programme, how reliable the vein-to-vein chain is, and how stable the provider's leadership is.
What you receive
- A written report that answers the questions agreed at scoping, with a clear verdict on each
- The read from the leaders running these businesses, gathered through our search work and attributed by role
- A data workbook with the underlying tables, so your team can filter, check and reuse the work
- A source register with the source and date behind each key fact
What can be in scope
- Manufacturing models: autologous and allogeneic, in-house and outsourced
- CDMO options by tier, capability and capacity
- Release, analytical and potency readiness
- Vein-to-vein logistics for the programme's markets
- Leadership stability across shortlisted providers
In cell and gene therapy the constraint has moved from steel to release and to people. Vector capacity can sit idle while fill-finish, potency assays and qualified leaders run short, and an autologous product depends on a chain of collection, courier, manufacture and return that no single quality system owns.
This assessment looks at manufacturing models, CDMO options, logistics and the stability of the teams behind them, scoped to a programme, a provider or an investment.
Who commissions it
- Developers choosing or changing a manufacturing partner
- Investors diligencing a CGT company or a CGT CDMO
- Partnering and corporate development teams
- Operations leaders planning a move to commercial supply
The questions it answers
- Which manufacturing model and CDMO tier fit the programme, from clinical supply to commercial scale?
- Is the binding constraint capacity, or release: assays, potency, vector analytics and the people who run them?
- Where does the vein-to-vein chain break: temperature, chain of custody, scheduling or cross-border release?
- How stable is a provider's site leadership, and what does turnover mean for a client programme?
- Which diligence questions apply to a CGT partner today that did not two years ago?
What you are buying access to
A proprietary intelligence base
Producers, facilities, pipelines, transactions, compensation and dated market signals across radiopharma, ADC, cell and gene therapy, CDMO and CRO, built and maintained by ProGen.
Access to the people who run it
Our executive search work puts us in conversation with the leaders of these businesses every week. Their read on the market goes into your answer.
Built around your decision
Scoped to the call in front of you: an investment, a partner, a supplier or a market. Every key fact sourced and dated.
How it works
Tell us your question
Choose an analysis below or describe your own. The more specific the decision, the sharper the scope.
Scope and quotation within one business day
We reply with the questions we will answer, what is in and out of scope, the timeline and a fixed quotation.
Your answer, built to stand up
A written report with a clear verdict, the read from the leaders in the space, a data workbook and a source register.
Request this analysis
Tell us the decision and the questions behind it. Within one business day you have the scope, the timeline and a fixed quotation.
Other analyses
- ADC Payload and Linker Supply AssessmentADC supply breaks at the payload. Who can actually make it at scale?
- CDMO Committed Capacity AssessmentHow much CDMO capacity can you actually book, and who booked it first?
- Leadership and Compensation BenchmarkWhat the leaders you need are paid, and how hard they are to hire.
